Evora Biosciences
Paris, France· Est.
Immunomodulatory lipopeptides are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, ophtalmology and respiratory care, as standalone drugs or as part of steroid-sparing therapeutic approaches.
Private Company
Total funding raised: $2.5M
About
Immunomodulatory lipopeptides are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, ophtalmology and respiratory care, as standalone drugs or as part of steroid-sparing therapeutic approaches.
Drug Delivery
Funding History
1Total raised:$2.5M
Seed$2.5M